Previous studies performed in pancreatic and hematological cancers have also revealed increased MARCKS expression and MARCKS phosphorylation in cancer cells that have developed resistance to drugs such as oxaliplatin and proteasome inhibitors [57,58,59,60]. This evidence concerns the gene MARCKS and hematopoietic and lymphoid cell neoplasm.